EDEN PRAIRIE, Minn.—SurModics Inc., a provider of drug delivery andsurface modification technologies to the healthcare industry, and NuPathe Inc.,a neuroscience-focused specialty pharmaceutical company, announced in Novemberthat they signed a license agreement for NP201, the first long-acting treatmentavailable in broadly acceptable dose form that maintains the potential toprovide sustained relief from Parkinson's disease without motor responsecomplications. NP201 leverages NuPathe's long-acting delivery technology andSurModics' biodegradable polymer matrix implant technology to achieve optimaldrug release over an extended period of time. Under the licensing agreement,NuPathe will lead and fund development and commercialization. SurModics willprovide technical and manufacturing expertise and will be eligible to receivelicensing fees and milestone payments related to development of products forthe treatment of Parkinson's disease and other clinical indications. SurModicswill also receive royalties on product sales.